About EDGAR Online | Login
 
The following is an excerpt from a 10-K SEC Filing, filed by ADVANCIS PHARMACEUTICAL CORP on 3/29/2006.
Next Section Next Section Previous Section Previous Section
MIDDLEBROOK PHARMACEUTICALS, INC. - 10-K - 20060329 - MARKET
 
PART II
 
Item 5.   Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities
 
Our common stock has been traded on The Nasdaq National Market under the symbol AVNC since October 17, 2003. The following table sets forth the quarterly high and low sales prices per share of our common stock as reported by Nasdaq for each quarter during the last two fiscal years, commencing on January 1, 2004:
 
                 
    HIGH     LOW  
 
December 31, 2005:
               
Fourth quarter
  $ 1.69     $ 1.20  
Third quarter
    2.75       0.86  
Second quarter
    5.40       1.70  
First quarter
    5.42       3.03  
December 31, 2004:
               
Fourth quarter
  $ 8.60     $ 2.50  
Third quarter
    9.05       6.73  
Second quarter
    9.74       6.58  
First quarter
    10.15       7.34  
 
As of February 28, 2006, there were 132 holders of record of our common stock. This figure does not represent the actual number of beneficial owners of our common stock because shares are generally held in “street name” by securities dealers and others for the benefit of individual owners who may vote the shares.
 
We have never declared or paid any cash dividends on our common stock. We currently intend to retain our future earnings, if any, to finance the further development and expansion of our business and do not intend to pay cash dividends for the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in current or future financing instruments and such other factors as our board of directors deems relevant.
 
From October 15, 2003, the effective date of our Registration Statement on Form S-1 (File No. 333-107599), to December 31, 2005, we have used the entire $54.3 million of the net offering proceeds from our initial public offering, as follows:
 
         
Purchase of Keflex intangible assets
  $ 11,206,000  
Purchases of property and equipment
    4,768,000  
Cash used for debt payments
    1,513,000  
Cash used in operating activities
    36,825,000  
         
Total
  $ 54,312,000  
         


30


Table of Contents